The National Immunization Advisory Committee (NACI) on Friday recommended that people who have experienced myocarditis or pericarditis after the first dose of the messenger RNA vaccine “wait until more information is available before receiving their second dose.”
• Read also: COVID-19: Quebec vaccination record
“We are closely monitoring the development of rare cases of myocarditis or pericarditis that occur after administration of the mRNA vaccine in young people. “NACI is encouraged that the clinical picture appears to be mild and is resolved rapidly,” NACI President D said in a statement.Return Shelley Dix.
In addition to this new precaution, the NACI also recommended that people receiving the mRNA vaccine should be aware of a “very rare risk of myocarditis or pericarditis after immunization.”
A small number of myocarditis, inflammation of the heart muscle, and pericarditis, an inflammation of the membrane surrounding the heart, have been reported in Canada and other countries after administration of the mRNA vaccine.
Cases were identified more frequently among young people under the age of 30 and more often after a second dose, the commission said, adding that the majority of cases were mild.
“I want to let Canadians know that the benefits of the COVID-19 mRNA vaccines still outweigh their potential risks. Dr Theresa Tam, Chief Public Health Officer, stressed that it is important that everyone receives their second dose of the vaccine in order to benefit from the best possible protection.
NACI continues to recommend “a full series of the mRNA vaccine for all eligible individuals, including those 12 years of age or older.”